Claims for Patent: 6,469,024

Summary for Patent: 6,469,024

Title:	Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
Abstract:	Tetrahydroisoquinoline analogs are provided which are useful in stimulating endogenous production or release of growth hormone and in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength. The tetrahdroisoquinoline analogs thereof have the structure ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.3a, X.sub.1, X.sub.2, X.sub.3, X.sub.4, m and n are as described herein.
Inventor(s):	Li; James J. (Pennington, NJ), Tino; Joseph A. (Lawrenceville, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	09/852,565
Patent Claims:	1. A compound which has the structure ##STR437## pharmaceutically acceptable salts, prodrug esters, and all stereoisomers thereof wherein R.sub.1 is alkyl, aryl, alkenyl, alkynyl, arylalkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkyl-alkoxy, alkoxyalkyl, alkylthioalkyl, aryloxyalkyl, arylalkoxyalkyl, cyclohetero-alkyl, cycloheteroalkylalkyl, heteroaryl, or heteroaryl-alkyl, and where these groups may be optionally substituted with 1 to 3 J1 groups which may be the same or different and the R.sub.1 aryls may be further optionally substituted with 1 to 5 halogens, aryl, --CF.sub.3, --OCF.sub.3, 1-3 hydroxyls, 2 of which substituents where possible, may be joined by a methylene bridge; R.sub.2 is H, alkyl, aryl, alkenyl, alkynyl, arylalkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, aryloxyalkyl, arylalkoxyalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkylalkoxy, heteroaryl, or heteroarylalkyl, and where these groups may be optionally substituted with a J1a group and the aryls may be further optionally substituted with 1 to 5 halogens, --CF.sub.3, --OCF.sub.3, or 1-3 hydroxyls; X is a bond, --O--, or --NR.sub.4 --; R.sub.3 and R.sub.3a are the same or different and are independently selected from H, alkoxy, halogen, --CF.sub.3, alkyl, or aryl; R.sub.4, R.sub.4a, R.sub.4b, R.sub.4c, R.sub.4d, R.sub.4e, R.sub.4f, R.sub.4g, R.sub.4h, R.sub.4i, R.sub.4j, R.sub.4k, and R.sub.4l are the same or different and are independently selected from H, C.sub.1 -C.sub.6 alkyl, or aryl; m and n are the same or different and are independently 0 or 1; Y is ##STR438## where x and y are the same or different and are independently 0 to 3 and z is 1 to 3; R.sub.5 and R.sub.5a are the same or different and are independently H, alkyl, alkoxy, hydroxyl, halogen, --CF.sub.3, aryl, alkaryl, and cycloalkyl; or R.sub.5 and R.sub.5a can be independently joined to one or both of R.sub.6 and R.sub.7 groups to form an alkylene bridge of 1 to 5 carbon atoms; or R.sub.5 and R.sub.5a can be joined together to form a ring of from 4-7 carbon atoms; X.sub.2 is ##STR439## R.sub.6 and R.sub.7 are the same or different and are independently selected from H and alkyl, where the alkyl may be optionally substituted with halogen, 1 to 3 hydroxyls, 1 to 3 C.sub.1 -C.sub.10 alkanoyloxy, 1 to 3 C.sub.1 -C.sub.6 alkoxy, phenyl, phenoxy, C.sub.1 -C.sub.6 alkoxycarbonyl; or R.sub.6 and R.sub.7 can together form --(CH.sub.2).sub.t X.sub.5 (CH.sub.2).sub.u -- where X.sub.5 is --C(R.sub.4c) (R.sub.4d)--, --O-- or --N(R.sub.4e)--, t and u are the same or different and are independently 1-3; R.sub.8 is H, C.sub.1 -C.sub.6 alkyl, --CF.sub.3, alkaryl, or aryl, and with the alkyl and aryl groups being optionally substituted with 1 to 3 hydroxyls, 1 to 3 C.sub.1 -C.sub.10 alkanoyloxy, 1 to 3 C.sub.1 -C.sub.6 alkoxy, phenyl, phenoxy or C.sub.1 -C.sub.6 alkoxycarbonyl; R.sub.9 and R.sub.10 are the same or different and are independently selected from H, C.sub.1 -C.sub.6 alkyl, --CF.sub.3, alkaryl, aryl, or halogen, and with the alkyl and aryl groups being optionally substituted with 1 to 3 hydroxyls, 1 to 3 C.sub.1 -C.sub.10 alkanoyloxy, 1 to 3 C.sub.1 -C.sub.6 alkoxy, phenyl, phenoxy or C.sub.1 -C.sub.6 alkoxycarbonyl; X.sub.3 is a bond, --C(O)--, --C(O)O--, --C(O) N(R.sub.4f)--, --S(O).sub.2 --, or --S(O).sub.2 N(R.sub.4f)--; X.sub.4 is a bond, --O--, --OC(O)--, --N(R.sub.4g)--, --N(R.sub.4g)C(O)--, --N(R.sub.4g)C(O)N(R.sub.4h)--, --N(R.sub.4g)S(O).sub.2 --, --N(R.sub.4g)S(O).sub.2 N(R.sub.4h), --OC(O)N(R.sub.4g)--, --C(O)--, --C(O)N(R.sub.4g)--, --S--, --S(O).sub.2 --, or --S(O).sub.2 N(R.sub.4g)--; J1 and J1a are the same or different and are independently nitro, halogen, hydroxyl, --OCF.sub.3, --CF.sub.3, alkyl, --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(0)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O) OT.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v NT.sub.1 (T.sub.1a), --(CH.sub.2).sub.v N(T.sub.1a) SO.sub.2 T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)T.sub.1, --(CH.sub.2).sub.v OC(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)T.sub.1, --(CH.sub.2).sub.v OC(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v OT.sub.1, --(CH.sub.2).sub.v SO.sub.2 T.sub.1, --(CH.sub.2).sub.v SO.sub.2 N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v C(O)T.sub.1, --(CH.sub.2).sub.v CH(OH)T.sub.1, or heteroaryl as defined below, with v being 0-3; T.sub.1, T.sub.1a and T.sub.1b are the same or different and are independently H, alkyl, alkenyl, alkynyl, lower alkythioalkyl, alkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, or cycloalkyl, each of which may be optionally substituted with halogen, hydroxyl, --C(O)NR.sub.4i R.sub.4j, --NR.sub.4i C(O)R.sub.4j, --CN, --N(R.sub.4i)SO.sub.2 R.sub.11, --OC(O)R.sub.4i, --SO.sub.2 NR.sub.4i R.sub.4j, --SOR.sub.11, --SO.sub.2 R.sub.11, alkoxy, --COOH, cycloheteroalkyl, or --C(O)OR.sub.11 ; with the proviso that T.sub.1 cannot be hydrogen when it is connected to sulfur as in SO.sub.2 T.sub.1 ; or T.sub.1 and T.sub.1a or T.sub.1 and T.sub.1b can together form --(CH.sub.2).sub.r X.sub.5a (CH.sub.2).sub.s -- where X.sub.5a is --C(R.sub.4k) (R.sub.4l)--, --O-- or --N(R.sub.4k k), where r and s are the same or different and are independently 1-3; R.sub.11 is C.sub.1 -C.sub.6 alkyl or aryl; provided (1) where m is 0 and n is 1, the moiety --X.sub.4 --R.sub.2 is other than alkyl or alkoxy; and (2) where X is a bond and X.sub.2 is amino, then m is 1. 2. The compound as defined in claim 1 having the structure ##STR440## 3. The compound as defined in claim 1 having the structure ##STR441## 4. The compound as defined in claim 1 having the following structure: ##STR442## 5. The compound as defined in claim 1 having the following structure: ##STR443## 6. The compound as defined in claim 1 wherein R.sub.1 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, aryloxyalkyl, heteroaryl, or heteroarylalkyl, any of which may be optionally substituted with a J1 group; R.sub.2 is alkyl, aryl, arylalkyl, alkoxyalkyl, aryloxyalkyl, heteroaryl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl, and these groups may be optionally substituted by J1a; R.sub.3 and R.sub.3a are the same or different and are independently selected from H, alkoxy, halogen, or --CF.sub.3 ; m and n are independently 0 or 1; X is O or --NR.sub.4 --; Y is ##STR444## where x and y are independently 0 to 3; R.sub.4 is H or C.sub.1 -C.sub.6 alkyl; R.sub.5 and R.sub.5a are the same or different and are independently selected from H, alkyl, or --CF.sub.3, or R.sub.5 and R.sub.5a can be independently joined to one or both of R.sub.6 and R.sub.7 groups to form an alkylene bridge of 1 to 5 carbon atoms; X.sub.2 is ##STR445## R.sub.6 and R.sub.7 are the same or different and are independently selected from H, or alkyl, where alkyl may be substituted with halogen, 1 to 2 hydroxyls, 1 to 2 C.sub.1 -C.sub.10 alkanoyloxy, 1 to 2 C.sub.1 -C.sub.6 alkoxy, phenyl, phenoxy, C.sub.1 -C.sub.6 alkoxycarbonyl; or R.sub.6 and R.sub.7 can together form --(CH.sub.2).sub.t X.sub.5 (CH.sub.2).sub.u -- where X.sub.5 is --C(R.sub.4c) (R.sub.4d)-- or --O--, t and u are the same or different and are independently 1-3; X.sub.3 is --C(O)--, --C(O)O--, or --S(O).sub.2 N (R.sub.4f); X.sub.4 is a bond, --O--, --OC(O)--, or --N(R.sub.4g)C(O)--; J1 is --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)OT.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v SO.sub.2 T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)T.sub.1, --(CH.sub.2).sub.v OC(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v OT.sub.1, --(CH.sub.2).sub.v SO.sub.2 N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v C(O)T.sub.1, or heteroaryl, with v being 0-2; J1a is halogen, --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OT.sub.1, or --(CH.sub.2).sub.v C(O)T.sub.1, with v being 0-2; and T.sub.1, T.sub.1a and T.sub.1b are the same or different and are independently selected from H, alkyl, aryl, alkaryl, or cycloalkyl each optionally substituted with halogen, hydroxyl or alkoxy; with the proviso that T.sub.1 cannot be hydrogen when it is connected sulfur as in SO.sub.2 T.sub.1. 7. The compound as defined in claim 1 wherein R.sub.1 is alkyl, aryl, arylakyl, cycloalkyl, or cycloalkylalkyl and where these groups may be optionally substituted with a J1 group; R.sub.2 is alkyl, aryl, arylalkyl, or cycloalkyl, and these groups may be optionally substituted by J1a; X is --NH or --NCH.sub.3 ; R.sub.3 and R.sub.3a are each H; m is 1; n is 0; Y is ##STR446## where x and y are independently 0 or 1, with the proviso that both cannot be 0; R.sub.5 and R.sub.5a are the same or different and are independently selected from H, alkyl, or --CF.sub.3 ; or R.sub.5 and R.sub.5a can be independently joined to one or both of R.sub.6 and R.sub.7 groups to form an alkylene bridge of 1 to 5 carbon atoms; X.sub.2 is ##STR447## R.sub.6 and R.sub.7 are the same or different and are independently selected from H or alkyl, where alkyl may be optionally substituted with halogen, or 1 to 2 hydroxyls; X.sub.3 is --C(O)--, --C(O)O--, or --S(O).sub.2 N(R.sub.4f)--; X.sub.4 is --O--, or --OC(O)--; J1 is --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)OT.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v SO.sub.2 T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)T.sub.1, --(CH.sub.2).sub.v OC(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v OT.sub.1, --(CH.sub.2).sub.v SO.sub.2 N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)T.sub.1, or heteroaryl as defined below, with v being 0-2; J1a is halogen, --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OT.sub.1, or --(CH.sub.2).sub.v C(O)T.sub.1, with v being 0-2; and T.sub.1, T.sub.1a and T.sub.1b are the same or different and are independently selected from H, alkyl, aryl, or alkaryl, optionally substituted with halogen, hydroxyl or alkoxy; with the proviso that T.sub.1 cannot be hydrogen when it is connected to sulfur as in SO.sub.2 T.sub.1. 8. The compound as defined in claim 1 wherein R.sub.1 is alkyl, aryl, arylakyl, cycloalkyl, heteroaryl or heteroarylalkyl and where these groups may be optionally substituted with a J1 group; R.sub.2 is aryl, arylalkyl, or cycloalkyl, where these groups may be optionally substituted with one or more J1a; X is --N(R.sub.4)-- where R.sub.4 is H or alkyl; R.sub.3 and R.sub.3a are each H; m is 1; n is 0; Y is ##STR448## where x and y are independently 0 or 1; R.sub.5 and R.sub.5a are the same or different and are independently selected from H, alkyl, or --CF.sub.3 ; X.sub.2 is ##STR449## R.sub.6 and R.sub.7 are the same or different and are independently selected from H or alkyl, where alkyl may be optionally substituted with halogen, or 1 to 2 hydroxyls; X.sub.3 is --C(O)--, --C(O)O--, --S(O).sub.2 -- or --S(O).sub.2 N(R.sub.4f)--; X.sub.4 is --O--, or --OC(O)--; J1 is alkyl, --(CH.sub.2).sub.v CN, --(CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)OT.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)C(O)N(T.sub.1b)T.sub.1, --(CH.sub.2).sub.v SO.sub.2 T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OC(O)T.sub.1, --(CH.sub.2).sub.v OC(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v N(T.sub.1a)SO.sub.2 N (T.sub.1b)T.sub.1, --(CH.sub.2).sub.v OT.sub.1, --(CH.sub.2).sub.v SO.sub.2 N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)T.sub.1, or heteroaryl as defined below, with v being 0-2; J1a is halogen, --CF.sub.3, --(CH.sub.2).sub.v CN, (CH.sub.2).sub.v N(T.sub.1a)C(O)T.sub.1, --(CH.sub.2).sub.v C(O)N(T.sub.1a)T.sub.1, --(CH.sub.2).sub.v C(O)OT.sub.1, --(CH.sub.2).sub.v OT.sub.1, or --(CH.sub.2).sub.v C(O)T.sub.1, with v being 0-2; and T.sub.1, T.sub.1a and T.sub.1b are the same or different and are independently selected from H, alkyl, aryl, or alkaryl, optionally substituted with halogen, hydroxyl or alkoxy; with the proviso that T.sub.1 cannot be hydrogen when it is connected to sulfur as in SO.sub.2 T.sub.1. 9. A compound as defined in claim 1 having the structure ##STR450## ##STR451## ##STR452## ##STR453## ##STR454## ##STR455## ##STR456## ##STR457## ##STR458## ##STR459## ##STR460## ##STR461## ##STR462## 10. The compound as defined in claim 8 having the structure ##STR463## ##STR464## ##STR465## ##STR466## ##STR467## ##STR468## ##STR469## ##STR470## 11. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor. 12. A pharmaceutical composition of claim 11 further comprising at least one additional therapeutic agent selected from parathyroid hormone, bisphosphonates, estrogen, testosterone, selective estrogen receptor modulators, selective androgen receptor modulators, progestin receptor agonists, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, or thyroid mimetics. 13. A method for increasing levels of endogenous growth hormone, which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 14. A method for treating obesity which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 15. A method for treating osteoporosis which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 16. A method for treating renal disease which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 17. A method for treating congestive heart failure, cardiac myopathy or cardiac dysfunction associated with valvular disease which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 18. A method for treating cachexia which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 19. A method for treating HIV wasting syndrome, muscular atrophy, lipodistrophy, long term critical illness, sarcopenia, stimulating wound healing and/or the immune system, increasing muscle mass and/or strength, maintaining muscle strength and function in the elderly, or treating fraility or ARFD in the elderly which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 20. A method for treating anorexia which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 21. A method for treating sleep disorders which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 22. A method for treating depression which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 23. A method for improving cognitive function which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 24. A method for improving the immune response to vaccination which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 25. A method for accelerating the recovery of hip fracture which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 26. A method for treating Syndrome X, which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 27. A method for treating diabetes and/or increasing lean body mass, which comprises administering a therapeutically effective amount of a compound as defined in claim 1 to a patient in need thereof. 28. A pharmaceutical composition of claim 11 further comprising at least one nutritional supplement. 29. A compound of claim 1 having the structure ##STR471## 30. A compound of claim 1 having the structure ##STR472##

Details for Patent 6,469,024

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2020-05-11